Survey reveals low awareness of innovative cancer treatment among Americans

Survey reveals low awareness of innovative cancer treatment among Americans

Roswell Park Comprehensive Cancer Center is at the forefront of a new approach to cancer treatment, called CAR T-cell therapy.

Survey Reveals Most Americans Unfamiliar with Breakthrough Cancer Treatment

Roswell Park Comprehensive Cancer Center is pioneering a transformative approach to cancer treatment known as CAR T-cell therapy, offering a beacon of hope for patients facing certain aggressive cancers. This sophisticated immunotherapy represents a significant paradigm shift in oncology, utilizing the patient’s own immune system to target and eradicate malignant cells without the need for invasive procedures. As awareness remains low among the …

Arovella tackles CAR-T’s limitations in cancer treatment with off-the-shelf innovation

Arovella Therapeutics at forefront of overcoming limitations of CAR-T cell therapy for cancer  Company uses healthy donor-derived iNKT cells, engineered with CARs to target specific cancer antigens Arovella looks to start phase I trial this year for lead product ALA-101   Special Report: Chimeric antigen receptor (CAR-T) cell therapy is a rapidly growing frontier in cancer research, with Australian biotech Arovella Therapeutics at the forefront …

Chimeric Antigen Receptor-Engineered Cell Membrane-Coated Nanoparticles Promote Dual-Targeted mRNA-Based Cancer Gene Therapy

Researchers demonstrated a CAR-inspired cancer cell membrane-coated platform for delivering an mRNA formulation through a dual tumor-targeted mechanism. [ACS Nano ] AbstractGraphical Abstract

# Pioneering Dual-Targeted CAR T-Cell Therapy FDA Grants RMAT Designation to Lyell Immunopharmas LYL314 for Relapsed...

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy Designation for LYL314 in Overcoming Persistent Large B-Cell Lymphoma' South San Francisco, California April 15, 2025' Lyell Immunopharma, Inc. (Nasdaq: LYEL), a leader in the clinical development of cutting-edge CAR T cell therapies, has made significant strides in its therapeutic pipeline with the recent designation of LYL314 (formerly known as IMPT314) as a Regenerative Medici…

FDA Grants RMAT Designation to ATSN-201 Gene Therapy for XLRS

A first-of-its-kind medication developed by Atsena Therapeutics, ATSN-201 has already received three other FDA designations.